| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gout | 120 | 2024 | 148 | 41.200 |
Why?
|
| Arthroplasty, Replacement, Knee | 72 | 2024 | 128 | 27.130 |
Why?
|
| Arthroplasty, Replacement, Hip | 65 | 2025 | 95 | 26.260 |
Why?
|
| Arthritis, Rheumatoid | 86 | 2024 | 261 | 24.480 |
Why?
|
| Antirheumatic Agents | 70 | 2024 | 121 | 21.370 |
Why?
|
| Rheumatology | 69 | 2025 | 119 | 17.580 |
Why?
|
| Gout Suppressants | 52 | 2021 | 62 | 13.740 |
Why?
|
| Allopurinol | 36 | 2020 | 71 | 12.030 |
Why?
|
| Osteoarthritis | 28 | 2025 | 86 | 11.010 |
Why?
|
| Osteoarthritis, Knee | 36 | 2024 | 244 | 10.430 |
Why?
|
| Lupus Erythematosus, Systemic | 20 | 2025 | 193 | 9.850 |
Why?
|
| Medicare | 37 | 2024 | 428 | 9.740 |
Why?
|
| Rheumatic Diseases | 37 | 2024 | 69 | 9.710 |
Why?
|
| Osteoarthritis, Hip | 25 | 2025 | 52 | 9.350 |
Why?
|
| Uric Acid | 36 | 2024 | 95 | 8.380 |
Why?
|
| Biological Products | 26 | 2024 | 122 | 7.900 |
Why?
|
| Hospitalization | 33 | 2025 | 1790 | 6.810 |
Why?
|
| Aged | 201 | 2025 | 19897 | 6.340 |
Why?
|
| Patient Participation | 18 | 2025 | 220 | 6.310 |
Why?
|
| Febuxostat | 18 | 2021 | 19 | 6.100 |
Why?
|
| Arthroplasty, Replacement | 15 | 2023 | 25 | 5.980 |
Why?
|
| United States | 137 | 2025 | 10938 | 5.970 |
Why?
|
| Patient Acceptance of Health Care | 17 | 2023 | 427 | 5.800 |
Why?
|
| Humans | 495 | 2025 | 125744 | 5.530 |
Why?
|
| Aged, 80 and over | 98 | 2024 | 6609 | 5.270 |
Why?
|
| Length of Stay | 31 | 2024 | 1313 | 5.240 |
Why?
|
| Hyperuricemia | 13 | 2022 | 38 | 5.170 |
Why?
|
| Middle Aged | 192 | 2025 | 27002 | 5.070 |
Why?
|
| Hospital Mortality | 24 | 2025 | 1027 | 4.980 |
Why?
|
| Postoperative Complications | 32 | 2025 | 3080 | 4.930 |
Why?
|
| Quality of Life | 53 | 2025 | 1952 | 4.720 |
Why?
|
| Comorbidity | 50 | 2025 | 1537 | 4.720 |
Why?
|
| Male | 257 | 2025 | 61807 | 4.680 |
Why?
|
| Female | 264 | 2025 | 67028 | 4.520 |
Why?
|
| Pain, Postoperative | 13 | 2023 | 260 | 3.980 |
Why?
|
| Decision Support Techniques | 7 | 2025 | 290 | 3.730 |
Why?
|
| Cohort Studies | 60 | 2025 | 4853 | 3.710 |
Why?
|
| Surgeons | 8 | 2023 | 257 | 3.660 |
Why?
|
| Treatment Outcome | 113 | 2024 | 12425 | 3.650 |
Why?
|
| Lupus Nephritis | 7 | 2019 | 44 | 3.610 |
Why?
|
| Risk Factors | 82 | 2025 | 10341 | 3.560 |
Why?
|
| Reoperation | 28 | 2020 | 834 | 3.550 |
Why?
|
| Immunosuppressive Agents | 10 | 2021 | 651 | 3.520 |
Why?
|
| Randomized Controlled Trials as Topic | 37 | 2024 | 1122 | 3.520 |
Why?
|
| Shoulder Joint | 10 | 2015 | 26 | 3.500 |
Why?
|
| Pain | 22 | 2023 | 451 | 3.480 |
Why?
|
| Knee Joint | 12 | 2022 | 158 | 3.470 |
Why?
|
| Clinical Trials as Topic | 32 | 2023 | 1106 | 3.400 |
Why?
|
| Pain Measurement | 34 | 2021 | 345 | 3.210 |
Why?
|
| Veterans | 21 | 2025 | 1748 | 3.190 |
Why?
|
| Activities of Daily Living | 16 | 2019 | 406 | 3.170 |
Why?
|
| Janus Kinase Inhibitors | 5 | 2023 | 22 | 3.060 |
Why?
|
| Periprosthetic Fractures | 7 | 2013 | 9 | 2.800 |
Why?
|
| Incidence | 45 | 2021 | 3155 | 2.750 |
Why?
|
| Substance-Related Disorders | 5 | 2021 | 461 | 2.630 |
Why?
|
| Methotrexate | 14 | 2022 | 334 | 2.560 |
Why?
|
| Registries | 21 | 2024 | 1436 | 2.490 |
Why?
|
| Hospital Charges | 10 | 2024 | 60 | 2.410 |
Why?
|
| Glucocorticoids | 12 | 2022 | 384 | 2.350 |
Why?
|
| Practice Guidelines as Topic | 21 | 2020 | 1274 | 2.310 |
Why?
|
| Healthcare Disparities | 8 | 2025 | 436 | 2.280 |
Why?
|
| Databases, Factual | 23 | 2024 | 1186 | 2.270 |
Why?
|
| Adult | 91 | 2025 | 29759 | 2.200 |
Why?
|
| Health Status | 17 | 2016 | 378 | 2.130 |
Why?
|
| Sex Factors | 26 | 2025 | 1288 | 2.110 |
Why?
|
| Vasculitis | 3 | 2021 | 50 | 2.110 |
Why?
|
| Pyrroles | 7 | 2018 | 184 | 2.110 |
Why?
|
| Piperidines | 7 | 2018 | 209 | 2.100 |
Why?
|
| Arthroplasty, Replacement, Ankle | 4 | 2019 | 4 | 2.080 |
Why?
|
| Antibodies, Monoclonal | 15 | 2020 | 1033 | 2.020 |
Why?
|
| Delivery of Health Care | 11 | 2022 | 616 | 1.970 |
Why?
|
| Cocaine | 3 | 2021 | 207 | 1.940 |
Why?
|
| Recovery of Function | 16 | 2017 | 446 | 1.940 |
Why?
|
| Humeral Head | 5 | 2012 | 6 | 1.920 |
Why?
|
| Surveys and Questionnaires | 36 | 2024 | 3744 | 1.920 |
Why?
|
| Arthritis, Psoriatic | 9 | 2022 | 17 | 1.920 |
Why?
|
| Pyrimidines | 7 | 2018 | 377 | 1.900 |
Why?
|
| Scleroderma, Systemic | 4 | 2020 | 119 | 1.890 |
Why?
|
| Self Report | 9 | 2021 | 516 | 1.870 |
Why?
|
| Cardiovascular Diseases | 11 | 2023 | 1970 | 1.870 |
Why?
|
| Multivariate Analysis | 19 | 2020 | 1444 | 1.870 |
Why?
|
| Proportional Hazards Models | 20 | 2020 | 1365 | 1.830 |
Why?
|
| Sjogren's Syndrome | 3 | 2020 | 87 | 1.830 |
Why?
|
| Plant Extracts | 4 | 2020 | 121 | 1.800 |
Why?
|
| Hip Joint | 5 | 2016 | 38 | 1.800 |
Why?
|
| Inpatients | 9 | 2025 | 500 | 1.790 |
Why?
|
| Communicable Diseases | 4 | 2021 | 161 | 1.780 |
Why?
|
| Chondrocalcinosis | 9 | 2025 | 13 | 1.780 |
Why?
|
| Severity of Illness Index | 32 | 2025 | 2918 | 1.750 |
Why?
|
| Time Factors | 33 | 2024 | 6356 | 1.740 |
Why?
|
| Dementia | 5 | 2018 | 451 | 1.730 |
Why?
|
| Arthralgia | 8 | 2021 | 56 | 1.720 |
Why?
|
| Age Factors | 26 | 2020 | 2833 | 1.720 |
Why?
|
| Myocardial Infarction | 8 | 2025 | 1050 | 1.710 |
Why?
|
| United States Department of Veterans Affairs | 14 | 2021 | 670 | 1.710 |
Why?
|
| Arthritis | 6 | 2024 | 81 | 1.700 |
Why?
|
| Fibromyalgia | 3 | 2024 | 19 | 1.690 |
Why?
|
| Risk Assessment | 25 | 2023 | 3470 | 1.660 |
Why?
|
| Arthritis, Juvenile | 5 | 2024 | 39 | 1.640 |
Why?
|
| Elective Surgical Procedures | 7 | 2025 | 160 | 1.620 |
Why?
|
| Prospective Studies | 33 | 2023 | 6173 | 1.610 |
Why?
|
| Telemedicine | 4 | 2022 | 439 | 1.610 |
Why?
|
| Physician-Patient Relations | 5 | 2022 | 430 | 1.590 |
Why?
|
| Logistic Models | 18 | 2021 | 1817 | 1.580 |
Why?
|
| Medication Adherence | 8 | 2019 | 399 | 1.570 |
Why?
|
| Qualitative Research | 6 | 2024 | 547 | 1.570 |
Why?
|
| Consensus | 27 | 2025 | 644 | 1.560 |
Why?
|
| Low Back Pain | 3 | 2022 | 36 | 1.560 |
Why?
|
| Hypertension | 10 | 2022 | 1332 | 1.540 |
Why?
|
| Retrospective Studies | 46 | 2024 | 16435 | 1.530 |
Why?
|
| Arthritis, Gouty | 3 | 2019 | 4 | 1.520 |
Why?
|
| Disease Management | 7 | 2020 | 532 | 1.520 |
Why?
|
| Patient Discharge | 9 | 2025 | 496 | 1.490 |
Why?
|
| Medicaid | 6 | 2021 | 243 | 1.460 |
Why?
|
| Cannabis | 2 | 2021 | 41 | 1.400 |
Why?
|
| Decision Making | 12 | 2019 | 657 | 1.400 |
Why?
|
| Patient Education as Topic | 6 | 2020 | 447 | 1.400 |
Why?
|
| Shoulder Pain | 4 | 2011 | 14 | 1.390 |
Why?
|
| Cross-Sectional Studies | 21 | 2025 | 3436 | 1.390 |
Why?
|
| Anti-Anxiety Agents | 2 | 2021 | 74 | 1.380 |
Why?
|
| Hallucinogens | 2 | 2021 | 43 | 1.350 |
Why?
|
| Prosthesis-Related Infections | 4 | 2019 | 179 | 1.350 |
Why?
|
| Hypothyroidism | 2 | 2023 | 91 | 1.350 |
Why?
|
| Patient Satisfaction | 9 | 2019 | 475 | 1.330 |
Why?
|
| Diabetes Mellitus | 10 | 2024 | 875 | 1.330 |
Why?
|
| Emergency Service, Hospital | 5 | 2018 | 1070 | 1.330 |
Why?
|
| Follow-Up Studies | 23 | 2022 | 5197 | 1.320 |
Why?
|
| Chronic Pain | 7 | 2021 | 126 | 1.320 |
Why?
|
| Myositis | 6 | 2024 | 62 | 1.310 |
Why?
|
| Spondylarthritis | 3 | 2020 | 8 | 1.270 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2016 | 320 | 1.270 |
Why?
|
| Rural Population | 3 | 2025 | 257 | 1.270 |
Why?
|
| Opioid-Related Disorders | 3 | 2023 | 264 | 1.250 |
Why?
|
| Evidence-Based Medicine | 14 | 2018 | 635 | 1.230 |
Why?
|
| Patient Readmission | 6 | 2019 | 385 | 1.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2021 | 512 | 1.210 |
Why?
|
| Alcoholism | 2 | 2021 | 231 | 1.190 |
Why?
|
| Osteonecrosis | 3 | 2023 | 11 | 1.190 |
Why?
|
| Disability Evaluation | 10 | 2016 | 189 | 1.170 |
Why?
|
| Giant Cell Arteritis | 2 | 2020 | 58 | 1.170 |
Why?
|
| Hemiarthroplasty | 3 | 2012 | 5 | 1.170 |
Why?
|
| Income | 3 | 2023 | 135 | 1.150 |
Why?
|
| Knee Prosthesis | 3 | 2013 | 10 | 1.140 |
Why?
|
| Odds Ratio | 13 | 2019 | 1261 | 1.140 |
Why?
|
| Spondylitis, Ankylosing | 6 | 2017 | 20 | 1.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 9 | 2020 | 307 | 1.120 |
Why?
|
| Urinary Tract Infections | 3 | 2021 | 299 | 1.120 |
Why?
|
| Attitude of Health Personnel | 5 | 2024 | 677 | 1.100 |
Why?
|
| Arthritis, Infectious | 2 | 2018 | 59 | 1.090 |
Why?
|
| Blood Transfusion | 4 | 2024 | 313 | 1.070 |
Why?
|
| Surgical Wound Infection | 5 | 2017 | 261 | 1.050 |
Why?
|
| Etanercept | 10 | 2020 | 40 | 1.050 |
Why?
|
| Sleep | 3 | 2019 | 346 | 1.050 |
Why?
|
| Sleep Wake Disorders | 2 | 2019 | 168 | 1.050 |
Why?
|
| Sepsis | 2 | 2021 | 482 | 1.030 |
Why?
|
| Health Surveys | 8 | 2019 | 245 | 1.030 |
Why?
|
| Orthopedic Surgeons | 4 | 2020 | 13 | 1.020 |
Why?
|
| Global Health | 14 | 2023 | 567 | 1.010 |
Why?
|
| Clinical Decision-Making | 3 | 2021 | 265 | 0.990 |
Why?
|
| Network Meta-Analysis | 5 | 2023 | 28 | 0.980 |
Why?
|
| Drug Therapy, Combination | 11 | 2022 | 1175 | 0.970 |
Why?
|
| Patient Reported Outcome Measures | 6 | 2023 | 173 | 0.960 |
Why?
|
| Obesity | 8 | 2024 | 2252 | 0.960 |
Why?
|
| Rituximab | 8 | 2024 | 159 | 0.950 |
Why?
|
| Arthroplasty, Replacement, Elbow | 2 | 2015 | 3 | 0.950 |
Why?
|
| Research | 4 | 2014 | 262 | 0.940 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2019 | 686 | 0.930 |
Why?
|
| Health Services | 4 | 2019 | 71 | 0.930 |
Why?
|
| Arthroplasty | 4 | 2015 | 16 | 0.920 |
Why?
|
| Urban Population | 2 | 2025 | 228 | 0.910 |
Why?
|
| Body Mass Index | 8 | 2024 | 1568 | 0.910 |
Why?
|
| Rheumatologists | 2 | 2021 | 9 | 0.900 |
Why?
|
| Joint Prosthesis | 4 | 2012 | 15 | 0.900 |
Why?
|
| Diabetes Complications | 2 | 2017 | 203 | 0.890 |
Why?
|
| Ambulatory Care | 2 | 2025 | 390 | 0.890 |
Why?
|
| Primary Health Care | 5 | 2022 | 777 | 0.880 |
Why?
|
| Teratogens | 1 | 2024 | 88 | 0.870 |
Why?
|
| Botulinum Toxins, Type A | 4 | 2010 | 167 | 0.870 |
Why?
|
| Cerebrovascular Disorders | 3 | 2015 | 122 | 0.860 |
Why?
|
| Opportunistic Infections | 2 | 2015 | 78 | 0.860 |
Why?
|
| Chronic Disease | 18 | 2025 | 1201 | 0.860 |
Why?
|
| Hip Fractures | 1 | 2024 | 67 | 0.860 |
Why?
|
| Abatacept | 9 | 2019 | 21 | 0.850 |
Why?
|
| Prognosis | 17 | 2021 | 4700 | 0.840 |
Why?
|
| Immunoconjugates | 5 | 2014 | 38 | 0.840 |
Why?
|
| Genetic Loci | 2 | 2022 | 342 | 0.820 |
Why?
|
| Minnesota | 9 | 2016 | 133 | 0.820 |
Why?
|
| Prosthesis Failure | 6 | 2013 | 158 | 0.820 |
Why?
|
| Arthroplasty, Replacement, Shoulder | 2 | 2020 | 4 | 0.820 |
Why?
|
| Patient-Centered Care | 4 | 2024 | 221 | 0.810 |
Why?
|
| Analgesics | 4 | 2021 | 127 | 0.810 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 548 | 0.810 |
Why?
|
| Health Services Accessibility | 5 | 2019 | 608 | 0.800 |
Why?
|
| Musculoskeletal Diseases | 6 | 2023 | 57 | 0.800 |
Why?
|
| Sex Distribution | 9 | 2020 | 309 | 0.800 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2022 | 4 | 0.800 |
Why?
|
| Cost of Illness | 5 | 2017 | 253 | 0.800 |
Why?
|
| Prostatectomy | 1 | 2024 | 344 | 0.790 |
Why?
|
| Public Health | 4 | 2020 | 267 | 0.790 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2022 | 23 | 0.790 |
Why?
|
| Pandemics | 6 | 2022 | 1114 | 0.790 |
Why?
|
| Biological Specimen Banks | 1 | 2022 | 51 | 0.790 |
Why?
|
| Stroke | 5 | 2019 | 990 | 0.790 |
Why?
|
| Uveitis | 2 | 2022 | 36 | 0.780 |
Why?
|
| Depression | 9 | 2018 | 1239 | 0.780 |
Why?
|
| Delphi Technique | 10 | 2025 | 210 | 0.780 |
Why?
|
| Health Status Disparities | 2 | 2016 | 228 | 0.770 |
Why?
|
| Gracilis Muscle | 1 | 2022 | 3 | 0.770 |
Why?
|
| Penile Implantation | 1 | 2022 | 24 | 0.770 |
Why?
|
| Rectal Fistula | 1 | 2022 | 4 | 0.770 |
Why?
|
| Symptom Flare Up | 7 | 2021 | 24 | 0.770 |
Why?
|
| Kidney Diseases | 2 | 2017 | 480 | 0.770 |
Why?
|
| Receptors, Tumor Necrosis Factor | 5 | 2015 | 70 | 0.760 |
Why?
|
| Age Distribution | 10 | 2021 | 421 | 0.760 |
Why?
|
| Urethral Diseases | 1 | 2022 | 18 | 0.760 |
Why?
|
| Penile Prosthesis | 1 | 2022 | 38 | 0.760 |
Why?
|
| Urinary Fistula | 1 | 2022 | 20 | 0.760 |
Why?
|
| Range of Motion, Articular | 5 | 2017 | 74 | 0.750 |
Why?
|
| Drug Monitoring | 3 | 2020 | 171 | 0.750 |
Why?
|
| Immunologic Factors | 3 | 2012 | 174 | 0.740 |
Why?
|
| Hearing Loss | 2 | 2023 | 135 | 0.740 |
Why?
|
| Global Burden of Disease | 6 | 2023 | 26 | 0.740 |
Why?
|
| Infliximab | 8 | 2018 | 65 | 0.730 |
Why?
|
| Thromboembolism | 3 | 2011 | 89 | 0.730 |
Why?
|
| Health Equity | 6 | 2017 | 58 | 0.730 |
Why?
|
| Botulinum Toxins | 4 | 2012 | 121 | 0.730 |
Why?
|
| Wounds and Injuries | 7 | 2020 | 370 | 0.730 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 643 | 0.720 |
Why?
|
| Peptic Ulcer | 2 | 2012 | 150 | 0.720 |
Why?
|
| Cannabidiol | 1 | 2021 | 22 | 0.720 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 5 | 2016 | 55 | 0.720 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2024 | 855 | 0.720 |
Why?
|
| Colchicine | 2 | 2020 | 44 | 0.710 |
Why?
|
| Marijuana Smoking | 1 | 2021 | 31 | 0.710 |
Why?
|
| Radiography | 11 | 2018 | 824 | 0.710 |
Why?
|
| Automobile Driving | 1 | 2021 | 30 | 0.710 |
Why?
|
| Physicians | 3 | 2022 | 589 | 0.710 |
Why?
|
| Marijuana Abuse | 1 | 2021 | 49 | 0.700 |
Why?
|
| Thiazoles | 2 | 2012 | 98 | 0.700 |
Why?
|
| Diagnostic Techniques and Procedures | 3 | 2019 | 30 | 0.700 |
Why?
|
| Diet Therapy | 2 | 2020 | 41 | 0.700 |
Why?
|
| Hospitals, Veterans | 5 | 2019 | 359 | 0.700 |
Why?
|
| Atrial Fibrillation | 2 | 2019 | 661 | 0.700 |
Why?
|
| Research Design | 16 | 2021 | 695 | 0.700 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 175 | 0.690 |
Why?
|
| Prunus domestica | 1 | 2020 | 1 | 0.690 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2016 | 604 | 0.690 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2020 | 1 | 0.690 |
Why?
|
| Ultrasonography | 3 | 2021 | 941 | 0.680 |
Why?
|
| Freedom | 1 | 2020 | 18 | 0.680 |
Why?
|
| Reproducibility of Results | 17 | 2021 | 2905 | 0.680 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2020 | 21 | 0.680 |
Why?
|
| Inflammation | 7 | 2022 | 1446 | 0.680 |
Why?
|
| Dissent and Disputes | 1 | 2020 | 32 | 0.680 |
Why?
|
| Robotic Surgical Procedures | 1 | 2024 | 207 | 0.680 |
Why?
|
| Health Status Indicators | 5 | 2019 | 124 | 0.670 |
Why?
|
| Polymyositis | 1 | 2020 | 7 | 0.670 |
Why?
|
| Adalimumab | 7 | 2022 | 26 | 0.670 |
Why?
|
| Attitude to Health | 3 | 2020 | 258 | 0.670 |
Why?
|
| Social Perception | 1 | 2020 | 56 | 0.660 |
Why?
|
| Dyslipidemias | 1 | 2022 | 234 | 0.660 |
Why?
|
| Tai Ji | 1 | 2019 | 4 | 0.650 |
Why?
|
| Speech | 1 | 2020 | 62 | 0.650 |
Why?
|
| Ankle Joint | 3 | 2015 | 35 | 0.650 |
Why?
|
| Finches | 1 | 2019 | 6 | 0.650 |
Why?
|
| Pneumonia | 3 | 2021 | 325 | 0.650 |
Why?
|
| Population Surveillance | 2 | 2019 | 389 | 0.650 |
Why?
|
| Erectile Dysfunction | 1 | 2022 | 198 | 0.640 |
Why?
|
| Knee Injuries | 1 | 2019 | 40 | 0.640 |
Why?
|
| Phytotherapy | 2 | 2020 | 51 | 0.640 |
Why?
|
| Advisory Committees | 1 | 2020 | 152 | 0.640 |
Why?
|
| Young Adult | 17 | 2025 | 9118 | 0.630 |
Why?
|
| Drug Prescriptions | 2 | 2018 | 221 | 0.620 |
Why?
|
| Hospitals, County | 1 | 2019 | 23 | 0.620 |
Why?
|
| Cocaine-Related Disorders | 1 | 2021 | 203 | 0.620 |
Why?
|
| Vulnerable Populations | 5 | 2017 | 140 | 0.620 |
Why?
|
| Culturally Competent Care | 1 | 2019 | 46 | 0.610 |
Why?
|
| Drug Hypersensitivity | 1 | 2020 | 95 | 0.610 |
Why?
|
| Congresses as Topic | 2 | 2017 | 175 | 0.610 |
Why?
|
| Heart Diseases | 3 | 2012 | 496 | 0.610 |
Why?
|
| Outpatient Clinics, Hospital | 3 | 2019 | 74 | 0.610 |
Why?
|
| Coronary Disease | 4 | 2021 | 679 | 0.600 |
Why?
|
| Forecasting | 5 | 2013 | 354 | 0.600 |
Why?
|
| Physical Therapy Modalities | 1 | 2018 | 52 | 0.600 |
Why?
|
| Polyethylene Glycols | 5 | 2016 | 240 | 0.600 |
Why?
|
| Electronic Health Records | 2 | 2025 | 722 | 0.600 |
Why?
|
| Quality-Adjusted Life Years | 10 | 2023 | 112 | 0.590 |
Why?
|
| Symptom Assessment | 4 | 2020 | 101 | 0.590 |
Why?
|
| Predictive Value of Tests | 10 | 2016 | 2183 | 0.580 |
Why?
|
| Hospitals, Low-Volume | 2 | 2015 | 31 | 0.580 |
Why?
|
| Hospitals, High-Volume | 2 | 2015 | 36 | 0.580 |
Why?
|
| Patient Preference | 3 | 2020 | 119 | 0.570 |
Why?
|
| Prevalence | 15 | 2023 | 2467 | 0.560 |
Why?
|
| Smoking | 3 | 2011 | 1051 | 0.560 |
Why?
|
| Spiro Compounds | 1 | 2017 | 13 | 0.560 |
Why?
|
| Patient Outcome Assessment | 2 | 2015 | 94 | 0.560 |
Why?
|
| Triazoles | 4 | 2019 | 139 | 0.550 |
Why?
|
| Sickness Impact Profile | 3 | 2011 | 36 | 0.550 |
Why?
|
| Calcium Pyrophosphate | 5 | 2025 | 7 | 0.550 |
Why?
|
| Sacroiliac Joint | 1 | 2017 | 5 | 0.550 |
Why?
|
| Furans | 1 | 2017 | 29 | 0.550 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 2110 | 0.540 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 172 | 0.540 |
Why?
|
| Substance P | 1 | 2017 | 36 | 0.540 |
Why?
|
| Back Pain | 1 | 2017 | 28 | 0.540 |
Why?
|
| Health Resources | 1 | 2018 | 116 | 0.530 |
Why?
|
| Macular Degeneration | 1 | 2018 | 115 | 0.530 |
Why?
|
| Urate Oxidase | 3 | 2012 | 17 | 0.530 |
Why?
|
| Physical Fitness | 3 | 2016 | 90 | 0.530 |
Why?
|
| Precision Medicine | 2 | 2017 | 322 | 0.520 |
Why?
|
| Chemokines | 1 | 2017 | 133 | 0.520 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2021 | 735 | 0.510 |
Why?
|
| Uricosuric Agents | 2 | 2020 | 5 | 0.510 |
Why?
|
| Review Literature as Topic | 5 | 2017 | 43 | 0.510 |
Why?
|
| Remission Induction | 7 | 2024 | 301 | 0.510 |
Why?
|
| Fees and Charges | 1 | 2016 | 10 | 0.510 |
Why?
|
| Tacrolimus | 1 | 2016 | 98 | 0.510 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 409 | 0.510 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2020 | 724 | 0.500 |
Why?
|
| Drug Substitution | 1 | 2015 | 20 | 0.500 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2024 | 1701 | 0.500 |
Why?
|
| Consumer Behavior | 1 | 2016 | 39 | 0.500 |
Why?
|
| Self Care | 1 | 2017 | 215 | 0.500 |
Why?
|
| Health Care Costs | 3 | 2016 | 373 | 0.500 |
Why?
|
| Tobacco Use | 1 | 2015 | 25 | 0.490 |
Why?
|
| Complementary Therapies | 1 | 2016 | 41 | 0.490 |
Why?
|
| Prosthesis Design | 3 | 2022 | 684 | 0.490 |
Why?
|
| Prunus | 1 | 2015 | 1 | 0.490 |
Why?
|
| Shoulder | 1 | 2015 | 29 | 0.490 |
Why?
|
| Fruit and Vegetable Juices | 1 | 2015 | 5 | 0.490 |
Why?
|
| Hospitals | 2 | 2024 | 398 | 0.490 |
Why?
|
| Drug Therapy | 1 | 2015 | 88 | 0.480 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 22 | 0.480 |
Why?
|
| Calcinosis | 3 | 2021 | 179 | 0.480 |
Why?
|
| Biological Factors | 1 | 2015 | 26 | 0.480 |
Why?
|
| Adjuvants, Immunologic | 1 | 2017 | 382 | 0.480 |
Why?
|
| Depressive Disorder | 1 | 2018 | 456 | 0.480 |
Why?
|
| Quadriceps Muscle | 1 | 2015 | 12 | 0.470 |
Why?
|
| Chondroitin Sulfates | 1 | 2015 | 13 | 0.470 |
Why?
|
| Evidence-Based Practice | 6 | 2024 | 112 | 0.470 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 206 | 0.470 |
Why?
|
| Dietary Supplements | 2 | 2016 | 471 | 0.470 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 122 | 0.460 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 361 | 0.460 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 377 | 0.460 |
Why?
|
| Cooperative Behavior | 2 | 2015 | 220 | 0.460 |
Why?
|
| Comparative Effectiveness Research | 4 | 2017 | 68 | 0.450 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2015 | 93 | 0.450 |
Why?
|
| International Classification of Diseases | 3 | 2015 | 91 | 0.450 |
Why?
|
| Cyclophosphamide | 1 | 2016 | 418 | 0.450 |
Why?
|
| Mortality | 3 | 2021 | 238 | 0.440 |
Why?
|
| Venous Thromboembolism | 1 | 2017 | 167 | 0.440 |
Why?
|
| Thioglycolates | 3 | 2019 | 13 | 0.440 |
Why?
|
| Peripheral Arterial Disease | 1 | 2018 | 292 | 0.440 |
Why?
|
| Knee Dislocation | 1 | 2013 | 2 | 0.440 |
Why?
|
| Hospital Costs | 3 | 2021 | 180 | 0.440 |
Why?
|
| Osteolysis | 1 | 2013 | 9 | 0.440 |
Why?
|
| Synovitis | 2 | 2004 | 25 | 0.440 |
Why?
|
| Prostatic Neoplasms | 2 | 2022 | 1549 | 0.430 |
Why?
|
| Feasibility Studies | 6 | 2020 | 764 | 0.430 |
Why?
|
| Plant Proteins | 3 | 2013 | 76 | 0.430 |
Why?
|
| Exercise | 3 | 2021 | 816 | 0.430 |
Why?
|
| Folic Acid Antagonists | 1 | 2013 | 16 | 0.430 |
Why?
|
| Brassica napus | 3 | 2012 | 4 | 0.430 |
Why?
|
| Placebos | 4 | 2021 | 241 | 0.430 |
Why?
|
| Biomarkers | 11 | 2022 | 3097 | 0.430 |
Why?
|
| Leucovorin | 1 | 2013 | 49 | 0.420 |
Why?
|
| Joint Instability | 1 | 2013 | 43 | 0.420 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 460 | 0.420 |
Why?
|
| Propensity Score | 3 | 2020 | 222 | 0.420 |
Why?
|
| Tuberculosis | 3 | 2017 | 526 | 0.410 |
Why?
|
| Survival Rate | 5 | 2021 | 2075 | 0.410 |
Why?
|
| HLA-B Antigens | 1 | 2013 | 28 | 0.410 |
Why?
|
| Health Personnel | 4 | 2021 | 509 | 0.410 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 237 | 0.410 |
Why?
|
| Drug Eruptions | 1 | 2013 | 32 | 0.400 |
Why?
|
| Administrative Claims, Healthcare | 3 | 2017 | 15 | 0.400 |
Why?
|
| Drug Delivery Systems | 4 | 2016 | 189 | 0.400 |
Why?
|
| Weight Loss | 3 | 2024 | 482 | 0.390 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 13 | 0.390 |
Why?
|
| Life Expectancy | 6 | 2020 | 53 | 0.380 |
Why?
|
| Patients | 3 | 2022 | 120 | 0.380 |
Why?
|
| Exercise Therapy | 3 | 2023 | 155 | 0.380 |
Why?
|
| Terminology as Topic | 2 | 2017 | 223 | 0.380 |
Why?
|
| Arabidopsis Proteins | 2 | 2013 | 40 | 0.380 |
Why?
|
| Parkinson Disease | 1 | 2019 | 690 | 0.370 |
Why?
|
| Sensitivity and Specificity | 8 | 2021 | 2060 | 0.370 |
Why?
|
| Regression Analysis | 3 | 2018 | 781 | 0.370 |
Why?
|
| Autoimmune Diseases | 3 | 2024 | 251 | 0.370 |
Why?
|
| Epidemiologic Methods | 5 | 2011 | 109 | 0.370 |
Why?
|
| Arabidopsis | 2 | 2013 | 71 | 0.370 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 590 | 0.360 |
Why?
|
| Pennsylvania | 3 | 2019 | 52 | 0.360 |
Why?
|
| Quality Assurance, Health Care | 3 | 2019 | 208 | 0.360 |
Why?
|
| Folic Acid | 1 | 2013 | 293 | 0.360 |
Why?
|
| Self-Help Devices | 1 | 2010 | 11 | 0.360 |
Why?
|
| Societies, Medical | 8 | 2021 | 699 | 0.350 |
Why?
|
| Treatment Failure | 4 | 2017 | 342 | 0.350 |
Why?
|
| Perioperative Care | 3 | 2017 | 195 | 0.350 |
Why?
|
| Internet | 4 | 2019 | 376 | 0.350 |
Why?
|
| Prostheses and Implants | 1 | 2012 | 152 | 0.350 |
Why?
|
| Photosynthesis | 2 | 2012 | 10 | 0.350 |
Why?
|
| Morbidity | 5 | 2020 | 249 | 0.340 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 238 | 0.340 |
Why?
|
| Insurance Claim Review | 3 | 2018 | 27 | 0.340 |
Why?
|
| Hypnotics and Sedatives | 2 | 2021 | 133 | 0.330 |
Why?
|
| Cluster Analysis | 3 | 2022 | 405 | 0.330 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2010 | 72 | 0.320 |
Why?
|
| Algorithms | 4 | 2016 | 1633 | 0.320 |
Why?
|
| Self Disclosure | 1 | 2009 | 24 | 0.320 |
Why?
|
| Efficiency | 1 | 2010 | 62 | 0.320 |
Why?
|
| Light-Harvesting Protein Complexes | 1 | 2009 | 1 | 0.320 |
Why?
|
| Sample Size | 1 | 2009 | 86 | 0.320 |
Why?
|
| Viral Core Proteins | 1 | 2009 | 22 | 0.320 |
Why?
|
| Databases as Topic | 1 | 2009 | 73 | 0.320 |
Why?
|
| Xanthine Oxidase | 2 | 2022 | 42 | 0.320 |
Why?
|
| Disease Progression | 6 | 2017 | 2090 | 0.320 |
Why?
|
| Spondylarthropathies | 1 | 2009 | 2 | 0.310 |
Why?
|
| Premenopause | 1 | 2009 | 31 | 0.310 |
Why?
|
| Longitudinal Studies | 7 | 2017 | 1334 | 0.310 |
Why?
|
| Transcription Factors | 3 | 2013 | 2603 | 0.310 |
Why?
|
| Neoplasms | 5 | 2017 | 2806 | 0.310 |
Why?
|
| Postoperative Period | 3 | 2016 | 335 | 0.300 |
Why?
|
| Organizational Innovation | 2 | 2021 | 45 | 0.300 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 881 | 0.300 |
Why?
|
| Anti-Dyskinesia Agents | 1 | 2008 | 39 | 0.300 |
Why?
|
| Immunoglobulin G | 6 | 2015 | 779 | 0.300 |
Why?
|
| Quality Indicators, Health Care | 1 | 2010 | 219 | 0.290 |
Why?
|
| Endpoint Determination | 2 | 2018 | 57 | 0.290 |
Why?
|
| Staphylococcus aureus | 1 | 2011 | 462 | 0.290 |
Why?
|
| Data Collection | 3 | 2022 | 382 | 0.290 |
Why?
|
| Bayes Theorem | 3 | 2021 | 285 | 0.290 |
Why?
|
| Adolescent | 13 | 2024 | 19478 | 0.280 |
Why?
|
| Interleukin-17 | 2 | 2018 | 120 | 0.280 |
Why?
|
| Fusarium | 1 | 2007 | 11 | 0.280 |
Why?
|
| Erythrocytes | 3 | 2017 | 219 | 0.280 |
Why?
|
| Quality of Health Care | 1 | 2010 | 392 | 0.280 |
Why?
|
| Anxiety | 4 | 2018 | 956 | 0.280 |
Why?
|
| Administration, Oral | 3 | 2023 | 684 | 0.280 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2007 | 47 | 0.280 |
Why?
|
| Meta-Analysis as Topic | 4 | 2017 | 162 | 0.270 |
Why?
|
| Patient Acuity | 2 | 2017 | 66 | 0.270 |
Why?
|
| Child Mortality | 2 | 2019 | 24 | 0.270 |
Why?
|
| Health Literacy | 3 | 2019 | 80 | 0.270 |
Why?
|
| Social Participation | 3 | 2016 | 20 | 0.270 |
Why?
|
| Bone and Bones | 1 | 2009 | 267 | 0.270 |
Why?
|
| Anxiety Disorders | 1 | 2013 | 689 | 0.270 |
Why?
|
| Double-Blind Method | 3 | 2017 | 1636 | 0.270 |
Why?
|
| Certolizumab Pegol | 2 | 2016 | 8 | 0.270 |
Why?
|
| Reference Values | 4 | 2017 | 719 | 0.260 |
Why?
|
| Staphylococcal Infections | 1 | 2011 | 562 | 0.260 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 2653 | 0.260 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2022 | 302 | 0.260 |
Why?
|
| Socioeconomic Factors | 7 | 2019 | 871 | 0.260 |
Why?
|
| Injections, Intra-Articular | 4 | 2010 | 26 | 0.260 |
Why?
|
| Bone Density | 1 | 2009 | 319 | 0.260 |
Why?
|
| Standard of Care | 2 | 2017 | 130 | 0.260 |
Why?
|
| Analysis of Variance | 3 | 2013 | 1021 | 0.260 |
Why?
|
| Diphtheria Toxoid | 1 | 2006 | 7 | 0.260 |
Why?
|
| Pain Management | 2 | 2019 | 178 | 0.260 |
Why?
|
| Infant Mortality | 2 | 2019 | 174 | 0.250 |
Why?
|
| Polyesters | 1 | 2006 | 39 | 0.250 |
Why?
|
| Interviews as Topic | 2 | 2025 | 374 | 0.250 |
Why?
|
| Pilot Projects | 5 | 2017 | 1398 | 0.250 |
Why?
|
| Immunity, Mucosal | 1 | 2006 | 87 | 0.250 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2018 | 244 | 0.250 |
Why?
|
| Nanostructures | 1 | 2006 | 50 | 0.250 |
Why?
|
| Freezing | 1 | 2005 | 28 | 0.250 |
Why?
|
| Utilization Review | 2 | 2016 | 40 | 0.240 |
Why?
|
| Health Care Surveys | 2 | 2021 | 285 | 0.240 |
Why?
|
| Skin | 2 | 2020 | 519 | 0.240 |
Why?
|
| Early Diagnosis | 2 | 2017 | 183 | 0.240 |
Why?
|
| Fatigue | 3 | 2024 | 188 | 0.240 |
Why?
|
| Insurance, Health | 2 | 2018 | 140 | 0.230 |
Why?
|
| Health Services Needs and Demand | 2 | 2016 | 175 | 0.230 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2024 | 6 | 0.230 |
Why?
|
| Proof of Concept Study | 1 | 2024 | 29 | 0.220 |
Why?
|
| Smoking Cessation | 2 | 2018 | 198 | 0.220 |
Why?
|
| Metacarpus | 1 | 2003 | 3 | 0.220 |
Why?
|
| Scaphoid Bone | 1 | 2003 | 3 | 0.220 |
Why?
|
| Communication | 2 | 2019 | 515 | 0.220 |
Why?
|
| Osteolysis, Essential | 1 | 2003 | 4 | 0.220 |
Why?
|
| Public Opinion | 2 | 2021 | 56 | 0.220 |
Why?
|
| Talus | 1 | 2003 | 7 | 0.220 |
Why?
|
| Hearing Aids | 1 | 2023 | 17 | 0.210 |
Why?
|
| Adaptation, Physiological | 1 | 2005 | 270 | 0.210 |
Why?
|
| Contraception | 1 | 2024 | 57 | 0.210 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2019 | 293 | 0.210 |
Why?
|
| Patella | 1 | 2003 | 25 | 0.210 |
Why?
|
| Escherichia coli | 1 | 2009 | 985 | 0.210 |
Why?
|
| Eczema | 1 | 2023 | 29 | 0.210 |
Why?
|
| Tinnitus | 1 | 2023 | 19 | 0.210 |
Why?
|
| Myocardial Contraction | 1 | 2005 | 268 | 0.210 |
Why?
|
| Acclimatization | 2 | 2013 | 14 | 0.210 |
Why?
|
| Dermatitis, Atopic | 1 | 2023 | 41 | 0.210 |
Why?
|
| Drug Design | 2 | 2015 | 153 | 0.200 |
Why?
|
| Vaccination | 2 | 2021 | 962 | 0.200 |
Why?
|
| Urinary Bladder | 1 | 2024 | 242 | 0.200 |
Why?
|
| Acute Disease | 5 | 2025 | 1111 | 0.200 |
Why?
|
| Disease Susceptibility | 2 | 2015 | 299 | 0.200 |
Why?
|
| Linear Models | 3 | 2016 | 687 | 0.200 |
Why?
|
| Consensus Development Conferences as Topic | 4 | 2015 | 39 | 0.200 |
Why?
|
| Overweight | 2 | 2017 | 364 | 0.200 |
Why?
|
| Case-Control Studies | 3 | 2018 | 3313 | 0.200 |
Why?
|
| Antigens | 2 | 2017 | 156 | 0.200 |
Why?
|
| United Kingdom | 1 | 2022 | 190 | 0.200 |
Why?
|
| Military Personnel | 1 | 2025 | 210 | 0.200 |
Why?
|
| Cementation | 2 | 2012 | 3 | 0.190 |
Why?
|
| Models, Statistical | 3 | 2015 | 472 | 0.190 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2014 | 12 | 0.190 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2014 | 63 | 0.190 |
Why?
|
| Amphetamines | 1 | 2021 | 10 | 0.190 |
Why?
|
| Spleen | 2 | 2017 | 281 | 0.190 |
Why?
|
| Organizations | 1 | 2021 | 16 | 0.190 |
Why?
|
| Observational Studies as Topic | 3 | 2020 | 88 | 0.180 |
Why?
|
| Adverse Outcome Pathways | 1 | 2021 | 1 | 0.180 |
Why?
|
| Volatilization | 1 | 2021 | 4 | 0.180 |
Why?
|
| Amphetamine | 1 | 2021 | 13 | 0.180 |
Why?
|
| Occupational Stress | 1 | 2021 | 11 | 0.180 |
Why?
|
| Mice, Inbred BALB C | 3 | 2017 | 1000 | 0.180 |
Why?
|
| Psychometrics | 4 | 2014 | 672 | 0.180 |
Why?
|
| Myristates | 1 | 2021 | 3 | 0.180 |
Why?
|
| Cetrimonium Compounds | 1 | 2021 | 4 | 0.180 |
Why?
|
| Stearic Acids | 1 | 2021 | 3 | 0.180 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 729 | 0.180 |
Why?
|
| Attitude to Computers | 1 | 2021 | 49 | 0.180 |
Why?
|
| Nicotinic Acids | 1 | 2021 | 7 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 235 | 0.180 |
Why?
|
| Simethicone | 1 | 2021 | 3 | 0.180 |
Why?
|
| New Zealand | 1 | 2021 | 51 | 0.180 |
Why?
|
| Dronabinol | 1 | 2021 | 31 | 0.180 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 275 | 0.180 |
Why?
|
| Job Satisfaction | 1 | 2021 | 81 | 0.180 |
Why?
|
| Organizational Culture | 1 | 2021 | 95 | 0.170 |
Why?
|
| Australia | 1 | 2021 | 139 | 0.170 |
Why?
|
| Physical Therapists | 1 | 2020 | 4 | 0.170 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 15 | 0.170 |
Why?
|
| Capsules | 1 | 2020 | 21 | 0.170 |
Why?
|
| Synovial Fluid | 1 | 2020 | 15 | 0.170 |
Why?
|
| Rotator Cuff Tear Arthropathy | 1 | 2020 | 2 | 0.170 |
Why?
|
| Rotator Cuff | 1 | 2020 | 6 | 0.170 |
Why?
|
| Government | 1 | 2020 | 13 | 0.170 |
Why?
|
| Diclofenac | 2 | 2017 | 6 | 0.170 |
Why?
|
| Bias | 1 | 2021 | 133 | 0.170 |
Why?
|
| Cytokines | 2 | 2017 | 1289 | 0.170 |
Why?
|
| Goals | 2 | 2018 | 128 | 0.170 |
Why?
|
| South Africa | 1 | 2020 | 99 | 0.170 |
Why?
|
| Workload | 1 | 2021 | 147 | 0.170 |
Why?
|
| Colitis, Ulcerative | 1 | 2022 | 205 | 0.170 |
Why?
|
| Drug Combinations | 1 | 2021 | 267 | 0.170 |
Why?
|
| Exercise Movement Techniques | 1 | 2019 | 3 | 0.170 |
Why?
|
| Long Term Adverse Effects | 1 | 2019 | 12 | 0.170 |
Why?
|
| Janus Kinase 1 | 1 | 2019 | 12 | 0.160 |
Why?
|
| Politics | 1 | 2020 | 59 | 0.160 |
Why?
|
| Midwestern United States | 2 | 2009 | 18 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 287 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1077 | 0.160 |
Why?
|
| International Cooperation | 2 | 2018 | 159 | 0.160 |
Why?
|
| Crohn Disease | 1 | 2022 | 279 | 0.160 |
Why?
|
| Patient Selection | 2 | 2015 | 701 | 0.160 |
Why?
|
| Myocardium | 1 | 2005 | 1022 | 0.160 |
Why?
|
| Pamphlets | 1 | 2019 | 23 | 0.160 |
Why?
|
| Arthritis, Reactive | 2 | 2009 | 4 | 0.160 |
Why?
|
| Los Angeles | 1 | 2019 | 16 | 0.160 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 145 | 0.160 |
Why?
|
| Patient Advocacy | 1 | 2019 | 62 | 0.160 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2019 | 32 | 0.160 |
Why?
|
| Enthesopathy | 1 | 2018 | 1 | 0.160 |
Why?
|
| Ustekinumab | 1 | 2018 | 2 | 0.160 |
Why?
|
| Spondylitis | 1 | 2018 | 7 | 0.160 |
Why?
|
| Interleukin-23 | 1 | 2018 | 12 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2020 | 130 | 0.150 |
Why?
|
| Professional-Patient Relations | 1 | 2019 | 84 | 0.150 |
Why?
|
| Workflow | 1 | 2019 | 118 | 0.150 |
Why?
|
| Nurses | 1 | 2019 | 67 | 0.150 |
Why?
|
| Hospitals, Community | 1 | 2019 | 55 | 0.150 |
Why?
|
| Social Class | 1 | 2019 | 190 | 0.150 |
Why?
|
| Risk | 2 | 2018 | 760 | 0.150 |
Why?
|
| Azetidines | 1 | 2018 | 58 | 0.150 |
Why?
|
| Occupational Therapy | 1 | 2018 | 35 | 0.150 |
Why?
|
| Interleukin-12 | 1 | 2018 | 116 | 0.150 |
Why?
|
| Purines | 1 | 2018 | 116 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2015 | 3175 | 0.150 |
Why?
|
| Choice Behavior | 1 | 2019 | 132 | 0.150 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 126 | 0.150 |
Why?
|
| Polyethyleneimine | 2 | 2016 | 10 | 0.150 |
Why?
|
| Creatinine | 2 | 2021 | 391 | 0.140 |
Why?
|
| Pyridines | 1 | 2019 | 235 | 0.140 |
Why?
|
| Learning | 1 | 2021 | 362 | 0.140 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 42 | 0.140 |
Why?
|
| Therapies, Investigational | 1 | 2017 | 12 | 0.140 |
Why?
|
| Blood Pressure | 2 | 2021 | 1377 | 0.140 |
Why?
|
| Hospitals, University | 2 | 2015 | 98 | 0.140 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2017 | 35 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 3 | 2015 | 513 | 0.140 |
Why?
|
| Macrophages, Peritoneal | 1 | 2017 | 37 | 0.140 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2017 | 33 | 0.140 |
Why?
|
| Free Radical Scavengers | 1 | 2017 | 54 | 0.140 |
Why?
|
| Patient Care Team | 1 | 2021 | 546 | 0.140 |
Why?
|
| Neck Pain | 1 | 2017 | 19 | 0.140 |
Why?
|
| Skin Transplantation | 1 | 2017 | 60 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 2017 | 93 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2011 | 772 | 0.130 |
Why?
|
| Leadership | 1 | 2019 | 230 | 0.130 |
Why?
|
| Manitoba | 1 | 2016 | 3 | 0.130 |
Why?
|
| Drug Synergism | 1 | 2017 | 228 | 0.130 |
Why?
|
| Sheep | 1 | 2017 | 220 | 0.130 |
Why?
|
| Sulfonamides | 1 | 2018 | 271 | 0.130 |
Why?
|
| Cyclosporine | 1 | 2017 | 147 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 290 | 0.130 |
Why?
|
| Checklist | 1 | 2017 | 86 | 0.130 |
Why?
|
| Rifampin | 1 | 2017 | 131 | 0.130 |
Why?
|
| Software | 2 | 2019 | 686 | 0.130 |
Why?
|
| Cold Temperature | 2 | 2013 | 78 | 0.130 |
Why?
|
| Stress, Psychological | 1 | 2021 | 560 | 0.130 |
Why?
|
| Protective Factors | 1 | 2016 | 85 | 0.130 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2016 | 68 | 0.130 |
Why?
|
| Preoperative Period | 1 | 2016 | 88 | 0.130 |
Why?
|
| Delayed-Action Preparations | 1 | 2016 | 110 | 0.130 |
Why?
|
| Pyrazoles | 1 | 2018 | 307 | 0.130 |
Why?
|
| Asthma | 1 | 2023 | 756 | 0.130 |
Why?
|
| Health Transition | 1 | 2015 | 10 | 0.120 |
Why?
|
| Animals | 8 | 2019 | 34367 | 0.120 |
Why?
|
| Aftercare | 1 | 2017 | 149 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2019 | 282 | 0.120 |
Why?
|
| Life Style | 1 | 2018 | 416 | 0.120 |
Why?
|
| Organic Anion Transporters | 1 | 2015 | 16 | 0.120 |
Why?
|
| Massachusetts | 1 | 2015 | 125 | 0.120 |
Why?
|
| Policy Making | 1 | 2015 | 59 | 0.120 |
Why?
|
| TWEAK Receptor | 1 | 2015 | 2 | 0.120 |
Why?
|
| Recurrence | 2 | 2025 | 1421 | 0.120 |
Why?
|
| Glucosamine | 1 | 2015 | 12 | 0.120 |
Why?
|
| Perception | 1 | 2016 | 220 | 0.120 |
Why?
|
| Arkansas | 1 | 2015 | 58 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2019 | 543 | 0.120 |
Why?
|
| Managed Care Programs | 1 | 2015 | 61 | 0.120 |
Why?
|
| Writing | 1 | 2015 | 62 | 0.120 |
Why?
|
| Occupational Diseases | 1 | 2015 | 75 | 0.120 |
Why?
|
| Acculturation | 1 | 2015 | 68 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 196 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1249 | 0.110 |
Why?
|
| Community Participation | 1 | 2014 | 44 | 0.110 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 230 | 0.110 |
Why?
|
| Happiness | 1 | 2014 | 10 | 0.110 |
Why?
|
| Ankle | 1 | 2014 | 29 | 0.110 |
Why?
|
| Hand | 1 | 2015 | 100 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 534 | 0.110 |
Why?
|
| Drug Costs | 2 | 2011 | 61 | 0.110 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2015 | 108 | 0.110 |
Why?
|
| Botrytis | 1 | 2013 | 1 | 0.110 |
Why?
|
| Diet | 1 | 2021 | 1140 | 0.110 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 130 | 0.110 |
Why?
|
| Oxylipins | 1 | 2013 | 5 | 0.110 |
Why?
|
| Mediterranean Region | 3 | 2018 | 7 | 0.110 |
Why?
|
| Mobility Limitation | 1 | 2013 | 26 | 0.110 |
Why?
|
| Hepatitis B | 1 | 2015 | 161 | 0.110 |
Why?
|
| Gene Frequency | 1 | 2015 | 726 | 0.110 |
Why?
|
| Cyclopentanes | 1 | 2013 | 20 | 0.110 |
Why?
|
| Motivation | 1 | 2016 | 319 | 0.110 |
Why?
|
| Phytochrome | 1 | 2013 | 1 | 0.110 |
Why?
|
| Plant Growth Regulators | 1 | 2013 | 7 | 0.110 |
Why?
|
| Patient Care Planning | 1 | 2014 | 122 | 0.110 |
Why?
|
| Hip Prosthesis | 1 | 2013 | 9 | 0.110 |
Why?
|
| Maternal Mortality | 1 | 2014 | 79 | 0.110 |
Why?
|
| Chloroplasts | 1 | 2013 | 9 | 0.110 |
Why?
|
| Orthopedics | 2 | 2017 | 67 | 0.110 |
Why?
|
| Graft Rejection | 1 | 2017 | 590 | 0.110 |
Why?
|
| Mental Health | 1 | 2016 | 347 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2019 | 646 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2015 | 220 | 0.100 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2017 | 383 | 0.100 |
Why?
|
| Biomechanical Phenomena | 1 | 2014 | 245 | 0.100 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 178 | 0.100 |
Why?
|
| Absorptiometry, Photon | 2 | 2015 | 178 | 0.100 |
Why?
|
| Educational Measurement | 1 | 2016 | 323 | 0.100 |
Why?
|
| Hepatitis C | 1 | 2017 | 367 | 0.100 |
Why?
|
| Affect | 1 | 2014 | 157 | 0.100 |
Why?
|
| Illness Behavior | 1 | 2013 | 7 | 0.100 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 104 | 0.100 |
Why?
|
| Mass Screening | 1 | 2018 | 787 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 280 | 0.100 |
Why?
|
| HIV Infections | 2 | 2022 | 1899 | 0.100 |
Why?
|
| Secondary Prevention | 2 | 2011 | 218 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3603 | 0.100 |
Why?
|
| Models, Genetic | 1 | 2015 | 761 | 0.100 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2012 | 7 | 0.100 |
Why?
|
| Single-Blind Method | 2 | 2011 | 240 | 0.100 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2012 | 28 | 0.100 |
Why?
|
| Military Medicine | 2 | 2010 | 49 | 0.100 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2012 | 24 | 0.100 |
Why?
|
| Efficiency, Organizational | 1 | 2012 | 54 | 0.100 |
Why?
|
| Organizational Objectives | 3 | 2019 | 33 | 0.100 |
Why?
|
| Tuberculin Test | 1 | 2013 | 123 | 0.100 |
Why?
|
| Education, Medical | 1 | 2016 | 289 | 0.100 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2012 | 43 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2012 | 286 | 0.100 |
Why?
|
| Rotator Cuff Injuries | 1 | 2011 | 6 | 0.100 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 185 | 0.090 |
Why?
|
| Alabama | 1 | 2011 | 45 | 0.090 |
Why?
|
| Child | 8 | 2020 | 24608 | 0.090 |
Why?
|
| Economics, Hospital | 1 | 2011 | 7 | 0.090 |
Why?
|
| Community Health Services | 1 | 2012 | 89 | 0.090 |
Why?
|
| Information Dissemination | 1 | 2013 | 187 | 0.090 |
Why?
|
| Neglected Diseases | 1 | 2014 | 151 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 2014 | 308 | 0.090 |
Why?
|
| National Health Programs | 1 | 2011 | 19 | 0.090 |
Why?
|
| Intraoperative Complications | 1 | 2012 | 172 | 0.090 |
Why?
|
| Human Rights | 1 | 2011 | 24 | 0.090 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 151 | 0.090 |
Why?
|
| Probability | 2 | 2017 | 322 | 0.090 |
Why?
|
| Carbon Dioxide | 1 | 2012 | 279 | 0.090 |
Why?
|
| Walkers | 1 | 2010 | 4 | 0.090 |
Why?
|
| Canada | 1 | 2012 | 291 | 0.090 |
Why?
|
| Dietary Sucrose | 1 | 2011 | 42 | 0.090 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2017 | 31 | 0.090 |
Why?
|
| Clinical Coding | 1 | 2010 | 13 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2011 | 52 | 0.090 |
Why?
|
| Urban Health | 1 | 2010 | 78 | 0.090 |
Why?
|
| Caregivers | 3 | 2021 | 578 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2014 | 343 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 376 | 0.090 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 142 | 0.080 |
Why?
|
| Device Removal | 1 | 2012 | 221 | 0.080 |
Why?
|
| Time | 1 | 2010 | 92 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 73 | 0.080 |
Why?
|
| MEDLINE | 1 | 2009 | 20 | 0.080 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 908 | 0.080 |
Why?
|
| Polyethylene | 1 | 2009 | 15 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 309 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 449 | 0.080 |
Why?
|
| Communicable Disease Control | 1 | 2011 | 138 | 0.080 |
Why?
|
| Quality Control | 1 | 2009 | 121 | 0.080 |
Why?
|
| Databases, Bibliographic | 1 | 2009 | 19 | 0.080 |
Why?
|
| Arthritis, Experimental | 1 | 2009 | 15 | 0.080 |
Why?
|
| Developing Countries | 1 | 2011 | 271 | 0.080 |
Why?
|
| Solubility | 1 | 2009 | 139 | 0.080 |
Why?
|
| Polyglycolic Acid | 2 | 2006 | 27 | 0.080 |
Why?
|
| Muscle, Skeletal | 3 | 2022 | 945 | 0.080 |
Why?
|
| Metatarsophalangeal Joint | 1 | 2008 | 3 | 0.080 |
Why?
|
| Heart Failure | 2 | 2020 | 2300 | 0.080 |
Why?
|
| Calcium, Dietary | 1 | 2009 | 37 | 0.080 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 119 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 705 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2016 | 1009 | 0.080 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2008 | 13 | 0.080 |
Why?
|
| Particle Size | 2 | 2006 | 124 | 0.080 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2009 | 58 | 0.080 |
Why?
|
| Walking | 1 | 2010 | 216 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 1728 | 0.080 |
Why?
|
| Stakeholder Participation | 2 | 2019 | 25 | 0.080 |
Why?
|
| Genotype | 2 | 2013 | 2569 | 0.080 |
Why?
|
| Internship and Residency | 1 | 2019 | 1184 | 0.070 |
Why?
|
| Muscle Strength | 1 | 2009 | 74 | 0.070 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 346 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 233 | 0.070 |
Why?
|
| Chromatography, Liquid | 1 | 2009 | 199 | 0.070 |
Why?
|
| Lactic Acid | 2 | 2006 | 153 | 0.070 |
Why?
|
| Polymers | 2 | 2006 | 104 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 230 | 0.070 |
Why?
|
| Regulon | 1 | 2007 | 11 | 0.070 |
Why?
|
| Health Services Research | 1 | 2009 | 186 | 0.070 |
Why?
|
| N-Glycosyl Hydrolases | 1 | 2007 | 14 | 0.070 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2007 | 32 | 0.070 |
Why?
|
| Phenotype | 2 | 2015 | 4271 | 0.070 |
Why?
|
| Medication Errors | 1 | 2009 | 187 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 427 | 0.070 |
Why?
|
| Europe | 2 | 2017 | 357 | 0.070 |
Why?
|
| Societies, Scientific | 1 | 2006 | 26 | 0.070 |
Why?
|
| Americas | 1 | 2006 | 50 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2009 | 490 | 0.060 |
Why?
|
| Carbon Monoxide | 1 | 2006 | 29 | 0.060 |
Why?
|
| Microscopy, Atomic Force | 1 | 2006 | 14 | 0.060 |
Why?
|
| Erythropoiesis | 1 | 2006 | 39 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2009 | 473 | 0.060 |
Why?
|
| Mental Health Services | 1 | 2009 | 259 | 0.060 |
Why?
|
| Energy Intake | 1 | 2009 | 494 | 0.060 |
Why?
|
| Body Composition | 1 | 2009 | 521 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2011 | 1522 | 0.060 |
Why?
|
| Cause of Death | 3 | 2014 | 477 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 2525 | 0.060 |
Why?
|
| Surface Properties | 1 | 2006 | 83 | 0.060 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2006 | 57 | 0.060 |
Why?
|
| Static Electricity | 1 | 2006 | 45 | 0.060 |
Why?
|
| Caco-2 Cells | 1 | 2006 | 94 | 0.060 |
Why?
|
| Administration, Intranasal | 1 | 2006 | 132 | 0.060 |
Why?
|
| Nasal Mucosa | 1 | 2006 | 66 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2006 | 194 | 0.060 |
Why?
|
| Immunization, Secondary | 1 | 2006 | 104 | 0.060 |
Why?
|
| Endocytosis | 1 | 2006 | 125 | 0.060 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 334 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2005 | 50 | 0.060 |
Why?
|
| Gene Regulatory Networks | 1 | 2007 | 363 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2004 | 39 | 0.060 |
Why?
|
| Mortality, Premature | 2 | 2015 | 12 | 0.060 |
Why?
|
| Synovial Membrane | 1 | 2004 | 27 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2007 | 372 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2006 | 325 | 0.060 |
Why?
|
| Vaccines, DNA | 1 | 2004 | 48 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 1298 | 0.060 |
Why?
|
| DNA Primers | 1 | 2005 | 658 | 0.060 |
Why?
|
| Cognition | 1 | 2009 | 729 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2013 | 4595 | 0.060 |
Why?
|
| Drug Carriers | 1 | 2004 | 100 | 0.060 |
Why?
|
| Immune System | 1 | 2004 | 90 | 0.050 |
Why?
|
| Isoxazoles | 1 | 2003 | 24 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 1034 | 0.050 |
Why?
|
| Biopsy | 2 | 2017 | 1242 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2006 | 420 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2006 | 505 | 0.050 |
Why?
|
| Myocarditis | 1 | 2005 | 129 | 0.050 |
Why?
|
| Diet, Reducing | 1 | 2024 | 89 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2003 | 42 | 0.050 |
Why?
|
| Catastrophization | 1 | 2023 | 15 | 0.050 |
Why?
|
| Receptors, Complement 3d | 1 | 2002 | 6 | 0.050 |
Why?
|
| Genes, Recessive | 1 | 2003 | 185 | 0.050 |
Why?
|
| Receptors, Complement 3b | 1 | 2002 | 9 | 0.050 |
Why?
|
| Infant | 5 | 2019 | 12597 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 122 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2022 | 114 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2004 | 410 | 0.050 |
Why?
|
| Siblings | 1 | 2003 | 198 | 0.050 |
Why?
|
| Anemia | 1 | 2006 | 339 | 0.050 |
Why?
|
| Infant, Newborn | 4 | 2019 | 8259 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2005 | 2831 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 295 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 1705 | 0.050 |
Why?
|
| HIV | 1 | 2022 | 180 | 0.050 |
Why?
|
| Diphosphates | 1 | 2021 | 6 | 0.050 |
Why?
|
| Muscles | 1 | 2022 | 292 | 0.050 |
Why?
|
| Toxicity Tests | 1 | 2021 | 35 | 0.050 |
Why?
|
| Child, Preschool | 5 | 2015 | 14140 | 0.040 |
Why?
|
| Translations | 1 | 2020 | 16 | 0.040 |
Why?
|
| Base Sequence | 1 | 2005 | 3108 | 0.040 |
Why?
|
| Syndrome | 1 | 2003 | 1121 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2022 | 211 | 0.040 |
Why?
|
| Germany | 1 | 2020 | 66 | 0.040 |
Why?
|
| Healthy Lifestyle | 1 | 2020 | 31 | 0.040 |
Why?
|
| Fibrosis | 1 | 2022 | 440 | 0.040 |
Why?
|
| United Nations | 1 | 2019 | 12 | 0.040 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2020 | 71 | 0.040 |
Why?
|
| Geography | 1 | 2019 | 115 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2002 | 435 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2022 | 524 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 175 | 0.040 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2021 | 259 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 1760 | 0.040 |
Why?
|
| Organizational Case Studies | 1 | 2017 | 26 | 0.040 |
Why?
|
| Colombia | 1 | 2017 | 48 | 0.040 |
Why?
|
| Djibouti | 1 | 2017 | 2 | 0.030 |
Why?
|
| Somalia | 1 | 2017 | 3 | 0.030 |
Why?
|
| Africa, Northern | 1 | 2017 | 9 | 0.030 |
Why?
|
| Middle East | 1 | 2017 | 34 | 0.030 |
Why?
|
| Mitochondria | 1 | 2022 | 680 | 0.030 |
Why?
|
| Demography | 1 | 2017 | 240 | 0.030 |
Why?
|
| Mice | 4 | 2009 | 17739 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2018 | 161 | 0.030 |
Why?
|
| Skin Absorption | 1 | 2016 | 7 | 0.030 |
Why?
|
| Excipients | 1 | 2016 | 11 | 0.030 |
Why?
|
| Drug Liberation | 1 | 2016 | 12 | 0.030 |
Why?
|
| Diuretics | 1 | 2017 | 171 | 0.030 |
Why?
|
| Drug Compounding | 1 | 2016 | 36 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2016 | 50 | 0.030 |
Why?
|
| Pregnancy | 2 | 2022 | 7222 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2016 | 67 | 0.030 |
Why?
|
| Permeability | 1 | 2016 | 125 | 0.030 |
Why?
|
| Bariatric Surgery | 1 | 2017 | 120 | 0.030 |
Why?
|
| Sanitation | 1 | 2015 | 17 | 0.030 |
Why?
|
| Metformin | 1 | 2017 | 151 | 0.030 |
Why?
|
| Temperature | 1 | 2016 | 307 | 0.030 |
Why?
|
| Knee | 1 | 2015 | 17 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2020 | 668 | 0.030 |
Why?
|
| Blood Sedimentation | 1 | 2015 | 29 | 0.030 |
Why?
|
| Self Administration | 1 | 2014 | 43 | 0.030 |
Why?
|
| Occupational Exposure | 1 | 2015 | 129 | 0.030 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 114 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 195 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 444 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 1694 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2014 | 94 | 0.030 |
Why?
|
| Developed Countries | 1 | 2013 | 37 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2015 | 316 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 358 | 0.030 |
Why?
|
| Melanoma | 1 | 2020 | 944 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 862 | 0.030 |
Why?
|
| Truth Disclosure | 1 | 2014 | 102 | 0.030 |
Why?
|
| Chlorophyll | 1 | 2012 | 4 | 0.030 |
Why?
|
| Plant Stomata | 1 | 2012 | 7 | 0.030 |
Why?
|
| American Recovery and Reinvestment Act | 1 | 2012 | 5 | 0.030 |
Why?
|
| Electron Transport | 1 | 2012 | 55 | 0.020 |
Why?
|
| Plants, Genetically Modified | 1 | 2012 | 42 | 0.020 |
Why?
|
| Publishing | 1 | 2013 | 109 | 0.020 |
Why?
|
| Health Behavior | 1 | 2015 | 385 | 0.020 |
Why?
|
| Economics, Pharmaceutical | 1 | 2012 | 8 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2013 | 442 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2014 | 604 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 433 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1902 | 0.020 |
Why?
|
| Light | 1 | 2012 | 176 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2014 | 377 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2011 | 33 | 0.020 |
Why?
|
| Occupational Health Services | 1 | 2011 | 6 | 0.020 |
Why?
|
| New York City | 1 | 2011 | 59 | 0.020 |
Why?
|
| Joints | 1 | 2011 | 23 | 0.020 |
Why?
|
| Quarantine | 1 | 2011 | 17 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2015 | 571 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2012 | 257 | 0.020 |
Why?
|
| Neurodegenerative Diseases | 1 | 2014 | 249 | 0.020 |
Why?
|
| Poverty | 1 | 2014 | 425 | 0.020 |
Why?
|
| Moral Obligations | 1 | 2011 | 74 | 0.020 |
Why?
|
| Survivors | 1 | 2013 | 341 | 0.020 |
Why?
|
| Confidentiality | 1 | 2011 | 99 | 0.020 |
Why?
|
| Personal Autonomy | 1 | 2011 | 202 | 0.020 |
Why?
|
| Kidney | 1 | 2016 | 1368 | 0.020 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2014 | 455 | 0.020 |
Why?
|
| Neuromuscular Agents | 1 | 2009 | 67 | 0.020 |
Why?
|
| DNA | 2 | 2004 | 1616 | 0.020 |
Why?
|
| Focus Groups | 1 | 2008 | 200 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2012 | 765 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2011 | 979 | 0.020 |
Why?
|
| Breath Tests | 1 | 2006 | 178 | 0.020 |
Why?
|
| Group II Phospholipases A2 | 1 | 2004 | 9 | 0.010 |
Why?
|
| Phospholipases A2 | 1 | 2004 | 37 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2006 | 311 | 0.010 |
Why?
|
| CHO Cells | 1 | 2004 | 169 | 0.010 |
Why?
|
| Peptides, Cyclic | 1 | 2004 | 55 | 0.010 |
Why?
|
| Cytosol | 1 | 2004 | 162 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 422 | 0.010 |
Why?
|
| Cell Survival | 1 | 2006 | 820 | 0.010 |
Why?
|
| Drug Approval | 1 | 2003 | 43 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2004 | 381 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2004 | 725 | 0.010 |
Why?
|
| Antibodies, Antinuclear | 1 | 2002 | 28 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 1506 | 0.010 |
Why?
|
| Androgens | 1 | 2004 | 279 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 2002 | 212 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 587 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 4415 | 0.010 |
Why?
|
| Rats | 1 | 2004 | 3727 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2004 | 3416 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2002 | 4419 | 0.010 |
Why?
|